{"id":20184,"date":"2026-11-16T05:20:36","date_gmt":"2026-11-16T08:20:36","guid":{"rendered":"https:\/\/rtmedical.com.br\/tmp-en-1794817235244\/"},"modified":"2026-11-16T05:20:43","modified_gmt":"2026-11-16T08:20:43","slug":"breast-cryoablation-pays-its-way","status":"publish","type":"post","link":"https:\/\/rtmedical.com.br\/en\/breast-cryoablation-pays-its-way\/","title":{"rendered":"Breast cryoablation can pay its way: RSNA 2026 data"},"content":{"rendered":"<p>Adding a <strong>breast cryoablation<\/strong> service line to an existing imaging practice can generate net revenue comparable to \u2014 or higher than \u2014 standard image-guided breast biopsies, without pushing the practice into a financial loss. That is the central message of a cost analysis from Mass General Brigham in Boston, set to be presented at RSNA 2026, which weighed what the procedure actually costs to deliver against what U.S. payers reimburse for it.<\/p>\n<p>The question has real urgency for practice managers. In 2025 the U.S. Food and Drug Administration cleared ultrasound-guided cryoablation for breast cancer treatment, and many groups now want to know whether offering it makes economic sense before investing in equipment and training. Janice Thai, MD, and colleagues built their answer from hospital purchasing data and billing records rather than list prices.<\/p>\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" class=\"alignright lazyload\" data-src=\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/11\/breast-cryoablation-cost-net-revenue.png\" alt=\"Bar chart comparing procedural cost and net revenue for breast cryoablation and three biopsy types in US dollars\" width=\"640\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1200px; --smush-placeholder-aspect-ratio: 1200\/630;\"><figcaption>Procedural cost versus net revenue by method. All figures are US-specific; data to be presented at RSNA 2026. Chart: RT Medical.<\/figcaption><\/figure>\n<h2>What the RSNA 2026 analysis measured<\/h2>\n<p>The research, scheduled for a women&#8217;s imaging session on December 2, 2026, modeled the financial and economic impact of launching a breast cancer cryoablation line inside an existing breast imaging practice. The team derived implementation costs from per-unit hospital purchase prices for argon cryogen, the cryoablation probe and disposable supplies, and pulled billing information from the electronic health record. It then compared the national average reimbursement for cryoablation with payments for four comparable procedures: ultrasound-, stereotactic-, contrast-enhanced mammography (CEM)\u2013 and MRI-guided biopsy.<\/p>\n<p>The dataset covered 50 procedures performed at a hospital outpatient breast imaging center between 2023 and 2026 \u2014 10 cryoablations and 10 of each biopsy type. That is a deliberately matched sample, but a small one, and all of it comes from a single institution.<\/p>\n<h2>Cryoablation costs more to perform, but returns more<\/h2>\n<p class=\"tex2jax_ignore\">Cryoablation was by far the most expensive procedure to carry out, averaging $1,940. The image-guided biopsies were much cheaper: $148.09 for ultrasound-guided, $298.80 for stereotactic, $320.15 for CEM-guided and $583.00 for MRI-guided. The economics flip on the reimbursement side. CMS paid $3,829.28 for cryoablation under CPT code 0581T, plus $139.10 for the initial physician consultation (CPT 99202), while global biopsy payments ranged from $1,766.77 to $1,791.68.<\/p>\n<p class=\"tex2jax_ignore\">After subtracting procedural cost from reimbursement, cryoablation netted $2,028.38, against $1,618.68 for ultrasound-guided, $1,477.35 for stereotactic and $1,208.68 for MRI-guided biopsy. Cryoablation therefore returned $409.70, $551.03 and $819.70 more than those three options, respectively \u2014 a gap the authors reported as statistically significant (p < 0.01). Because the global biopsy payments sat in a narrow band, from $1,766.77 to $1,791.68, most of the net-revenue spread is explained by procedural cost rather than by how much payers reimburse. The team concluded that practices \"can add the service line without incurring a financial loss.\" The one caveat they flagged: for CEM-guided biopsy the payment-to-charge ratio diverged, driven by commercial-payer differences.<\/p>\n<h2>What breast cryoablation is and who it suits<\/h2>\n<p>Cryoablation is a percutaneous, image-guided technique that destroys tissue with extreme cold. A thin probe is advanced into the lesion under ultrasound guidance, and argon-gas cycles form an ice ball that freezes and kills the target tissue; the procedure is typically done on an outpatient basis under local anesthesia, with no surgical incision. For breast care it is generally positioned as an option for selected patients with small, low-risk, early-stage tumors \u2014 and for benign lesions such as fibroadenomas \u2014 who prefer to avoid surgery or are not ideal surgical candidates. Eligibility is individualized, and the technique does not replace surgery, radiation or systemic therapy for most patients. The FDA&#8217;s 2025 clearance matters because it moves a treatment, not just a diagnostic step, into the imaging suite, which is what makes the service-line economics worth modeling in the first place. Because it runs on <a href=\"https:\/\/rtmedical.com.br\/en\/qt-imaging-cpt-3d-breast-ultrasound\/\">ultrasound-guided breast imaging<\/a>, a practice already equipped for biopsy owns much of the hardware and skill base it requires.<\/p>\n<h2>Reimbursement caveats and the view from Brazil<\/h2>\n<p>Two cautions matter before reading these numbers as a business case. First, every figure here is US-specific. CPT 0581T is a U.S. Category III code for an emerging service, and Category III codes are often not separately or consistently reimbursed by commercial payers, so real-world payment can differ sharply from the CMS national average. Coverage should be confirmed payer by payer, and it shifts as code sets are revised \u2014 the <a href=\"https:\/\/rtmedical.com.br\/en\/cpt-2027-code-set-radiology\/\">2027 CPT update<\/a> and the way <a href=\"https:\/\/rtmedical.com.br\/en\/acr-impact-tables-medicare-2027\/\">Medicare payment moves year to year<\/a> both illustrate how quickly the ground can change.<\/p>\n<p>Second, none of these dollar amounts carry over to Brazil. Here, imaging and interventional procedures are paid through the SUS schedule for public care and through ANS-regulated private plans that use the TUSS and CBHPM code sets, not CPT or CMS. Percutaneous ablation is well established in the country for other organs, but breast cryoablation is still emerging and lacks a dedicated, widely reimbursed code. Any local practice would have to rebuild the cost-and-revenue model against its own purchase prices and the ANS procedure list before judging whether the service line is viable.<\/p>\n<h2>Limitations and what to watch<\/h2>\n<p>This is a single-center analysis of 50 procedures presented as a conference preview, not a peer-reviewed, multi-site study, and the economic result says nothing about clinical outcomes \u2014 recurrence, cosmesis and long-term oncologic safety are separate questions that cryoablation still has to answer in larger trials. The payment landscape for Category III codes can also change quickly as payers revisit coverage. Even so, the core finding is useful for planning: on cost alone, a cryoablation line need not be a money-loser, which removes one barrier to offering patients a less invasive treatment option.<\/p>\n<p><strong>Source:<\/strong> <a href=\"https:\/\/www.auntminnie.com\/resources\/conference\/rsna\/2026\/womens-imaging-preview\/article\/16425487\/breast-cryoablation-could-pay-its-way-in-imaging-practices\" target=\"_blank\" rel=\"noopener\">AuntMinnie \u2014 Breast cryoablation could pay its way in imaging practices<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Breast cryoablation can match or beat biopsy net revenue, RSNA 2026 data suggest. See the US cost figures and what they mean for practices.<\/p>\n","protected":false},"author":5,"featured_media":20154,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0,"_rt_cluster":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[234,100],"tags":[],"class_list":["post-20184","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medical-billing","category-radiology"],"aioseo_notices":[],"rt_seo":{"title":"","description":"Breast cryoablation can match or beat biopsy net revenue, RSNA 2026 data suggest. See the US cost figures and what they mean for practices.","canonical":"","og_image":"","robots":"index,follow","schema_type":"Article","include_in_llms":true,"llms_label":"Breast cryoablation economics","llms_summary":"A Mass General Brigham cost analysis to be presented at RSNA 2026 finds a breast cryoablation service line yields net revenue equal to or above image-guided biopsies; all figures are US-specific dollars.","faq_items":[],"video":[],"gtin":"","mpn":"","brand":"","aggregate_rating":[]},"_links":{"self":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20184\/"}],"collection":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/"}],"about":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/types\/post\/"}],"author":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/users\/5\/"}],"replies":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/comments\/?post=20184"}],"version-history":[{"count":1,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20184\/revisions\/"}],"predecessor-version":[{"id":20186,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20184\/revisions\/20186\/"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/20154\/"}],"wp:attachment":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/?parent=20184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/categories\/?post=20184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/tags\/?post=20184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}